| Name | Antazoline hydrochloride |
| Description | Antazoline hydrochloride (Phenazoline hydrochloride), a first-generation antihistamine, can bind to the histamine H1 receptor and block the action of endogenous histamine. |
| In vitro | In the model of sustained epileptic state induced by picrotoxin, Antazoline can be utilized to protect the intrinsic neural circuitry. |
| In vivo | At a concentration of 30 μM, Antazoline effectively reduces neurotoxicity mediated by NMDA and also blocks NMDA-induced currents via a voltage-dependent and rapidly reversible action, with an inhibition rate of 85±3% at a voltage of -60 mV. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 45 mg/mL (149.1 mM), Sonication is recommended.
H2O : 14 mg/mL (46.39 mM), Sonication is recommended.
Ethanol : 4 mg/mL (13.25 mM), Sonication is recommended.
|
| Keywords | Phenazoline Hydrochloride | Phenazoline | Inhibitor | inhibit | HistamineReceptor | Histamine Receptor | H1 receptor | Antazoline Hydrochloride | Antazoline hydrochloride | Antazoline |
| Inhibitors Related | Chlorphenesin | Histamine dihydrochloride | Meclizine dihydrochloride | Mirtazapine | Lidocaine | Famotidine | Mebhydrolin napadisylate | Sodium butanoate | Amitriptyline hydrochloride | Alginic acid | Trazodone hydrochloride | Mianserin hydrochloride |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Bitter Compound library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Drug Library |
United States
